Joao Vinagre
Overview
Explore the profile of Joao Vinagre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bessa-Goncalves M, Bras J, Jesus T, Prazeres H, Soares P, Vinagre J
Genes (Basel)
. 2024 Nov;
15(11).
PMID: 39596624
Background: The screening of TERT promoter () mutations is essential in cancer research and diagnostics, due to its prevalence in tumours associated with low self-renewal rates. TERTmonitor is a diagnosis...
2.
Rodrigues L, Da Cruz Paula A, Soares P, Vinagre J
Cells
. 2024 Apr;
13(7.
PMID: 38607000
MicroRNAs (miRNAs) act as negative regulators for protein-coding gene expression impacting cell proliferation, differentiation, and survival. These miRNAs are frequently dysregulated in cancer and constitute classes of blood-based biomarkers useful...
3.
Teixeira E, Fernandes C, Bungardean M, Da Cruz Paula A, Lima R, Batista R, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338801
In a family with Familial Non-Medullary Thyroid Carcinoma (FNMTC), our investigation using Whole-Exome Sequencing (WES) uncovered a novel germline mutation []. USP42 is known for regulating p53, cell cycle arrest,...
4.
Bras J, Jesus T, Prazeres H, Lima J, Soares P, Vinagre J
Genes (Basel)
. 2023 Sep;
14(9).
PMID: 37761833
Telomerase promoter (TERTp) mutations are frequently observed in various types of tumours and commonly characterised by two specific hotspots located at positions -124 and -146 upstream of the start codon....
5.
Martins R, Jesus T, Cardoso L, Soares P, Vinagre J
J Pers Med
. 2023 Jul;
13(7).
PMID: 37511745
Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its low mutational...
6.
Gaspar T, Jesus T, Azevedo M, Macedo S, Soares M, Martins R, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296979
Atrx loss was recently ascertained as insufficient to drive pancreatic neuroendocrine tumour (PanNET) formation in mice islets. We have identified a preponderant role of Atrx in the endocrine dysfunction in...
7.
Ropio J, Prochazkova-Carlotti M, Batista R, Pestana A, Chebly A, Ferrer J, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833366
As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary...
8.
Rodrigues L, Canberk S, Macedo S, Soares P, Vinagre J
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499151
DGCR8 emerged recently as miRNAs biogenesis pathway protein with a highlighted role in thyroid disease. This study aimed to characterize this miRNA biogenesis component, in particular the p.(E518K) mutation and...
9.
Gaspar T, Lopes J, Soares P, Vinagre J
Endocr Relat Cancer
. 2022 Oct;
29(12):R191-R208.
PMID: 36197786
Pancreatic neuroendocrine neoplasms (PanNENs) are rare and clinically challenging entities. At the molecular level, PanNENs' genetic profile is well characterized, but there is limited knowledge regarding the contribution of the...
10.
Santos M, Ferreira M, Oliveira P, Mendes N, Andre A, Vieira A, et al.
Biology (Basel)
. 2022 Sep;
11(7).
PMID: 36101425
Transitions between epithelial and mesenchymal cellular states (EMT/MET) contribute to cancer progression. We hypothesize that EMT followed by MET promotes cell population heterogeneity, favouring tumour growth. We developed an EMT...